Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sonidegib - Sun Pharmaceutical Industries

Drug Profile

Sonidegib - Sun Pharmaceutical Industries

Alternative Names: Erismodegib; Erismodegib-phosphate; LDE-225; NVP-LDE-225; Odomzo; Sonidegib-phosphate

Latest Information Update: 02 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Groupe Francophone des Myelodysplasies; Massachusetts General Hospital; Mayo Clinic; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Novartis; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Stanford University; University of Alabama at Birmingham
  • Class Antineoplastics; Biphenyl compounds; Morpholines; Phenyl ethers; Pyridines; Small molecules
  • Mechanism of Action SMO protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Basal cell cancer
  • Phase II Haematological malignancies; Medulloblastoma; Multiple myeloma; Solid tumours
  • Phase I/II Myelofibrosis; Pancreatic cancer
  • Phase I Breast cancer
  • No development reported Chronic myeloid leukaemia; Graft-versus-host disease; Liver cancer; Myelodysplastic syndromes; Oesophageal cancer; Ovarian cancer; Prostate cancer; Small cell lung cancer
  • Discontinued Basal cell nevus syndrome

Most Recent Events

  • 19 Jun 2019 Novartis withdraws a phase Ib trial in Prostate cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (NCT02182622)
  • 01 Mar 2019 Updated 42-month adverse events data from the phase II BOLT trial in Basal cell cancer presented at the 77th Annual Meeting of the American Academy of Dermatology (AAD-2019)
  • 01 Mar 2019 Updated 42-month efficacy data from the phase II BOLT trial in Basal cell cancer presented at the 77th Annual Meeting of the American Academy of Dermatology (AAD-2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top